in vivo News and Research

RSS

Blocking nitric oxide suppresses tumor growth in aggressive pediatric neuroblastoma

The tumor begins before birth. Somewhere in the developing fetus, neural crest cells that should have matured into adrenal tissue or sympathetic ganglia take a wrong turn, and a child is born harboring a malignancy that may not declare itself for months.

7 Apr 2026

Prickly pear may pack a surprising punch against metabolic syndrome

This narrative review examines how Opuntia ficus-indica fruit, or prickly pear, may help target multiple features of metabolic syndrome through its fiber, betalains, polyphenols, carotenoids, and other bioactive compounds. The authors conclude that the fruit shows promising mechanistic and preclinical potential, but stronger human trials are still needed before firm clinical claims can be made.

6 Apr 2026

AI helps researchers find antimicrobial peptides in Earth’s harshest habitats

Researchers built the Extreme Environment Microbiome Catalog from 78,213 genomes across global extreme habitats, revealing major taxonomic and biosynthetic novelty, including 32,715 representative species, nearly 4 billion non-redundant genes, and 163,693 biosynthetic gene clusters. They then used protein language models to identify 3,032 candidate non-toxic antimicrobial peptides, with 84 of 100 synthesized peptides showing antibacterial activity and low cytotoxicity in the 50 tested in mammalian cells.

6 Apr 2026

Small molecule may block protein buildup in neurodegenerative diseases

A team of researchers from NYU Abu Dhabi and the University of Denver have identified a promising small molecule that could help slow or halt the progression of serious brain diseases such as Parkinson's disease, offering new hope for treatments that go beyond managing symptoms.

1 Apr 2026

New therapy reprograms immune cells to reduce asthma inflammation

A collaborative effort between researchers at the Henan Academy of Innovations in Medical Science, Zhengzhou University, and Shenzhen University School of Medicine has provided the first proof-of-principle study demonstrating that targeting a receptor on the surface of anti-inflammatory regulatory T cells (Tregs) can restore their function and alleviate asthma in mice.

31 Mar 2026

Lipid nanoparticles help CAR T cells melt pancreatic cancer barriers

Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has one of the lowest rates of survival among major malignancies.

31 Mar 2026

Collaboration advances EMA601 as potential first-in-class stroke therapy

Boehringer Ingelheim and the Lower Franconian biotech company EMFRET Analytics have signed a cooperation and license agreement for the preclinical development program of the GPVI‑blocking antibody EMA601.

30 Mar 2026

Natural peptide in sweat may help block flu infection before symptoms start

Researchers led by the Fisabio Foundation found that dermcidin, a natural antimicrobial peptide present in sweat and respiratory tissues, can block influenza infection by binding to a highly conserved region of the viral hemagglutinin protein and preventing cell entry. The study also found that people who did not develop flu-like symptoms had markedly higher baseline dermcidin levels, suggesting the molecule may help reduce susceptibility to infection and could support the development of broader-spectrum antivirals.

30 Mar 2026

Nuclera launches GPCR-focused nanodisc panel to streamline membrane protein production

Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today announced the launch of its nanodisc panel to support screening and scale-up of G-Protein Coupled Receptors (GPCRs).

From Nuclera 30 Mar 2026

Dandelion leaves boost brain-protective compounds after digestion

Dandelion leaves are rich in polyphenols with neuroprotective effects, offering insights into natural strategies for Alzheimer's disease management.

27 Mar 2026

Microfluidic chips enable realistic modeling of tumor immune environments

The challenge is that the tumor immune microenvironment is not a static backdrop but a constantly shifting ecosystem shaped by cancer cells, immune cells, stromal cells, cytokines, and physical barriers.

26 Mar 2026

Can camel milk improve health? Review highlights benefits but warns against drinking it raw

A narrative review in Food Science & Nutrition examined studies published from 2000 to 2025 and found that camel milk contains bioactive compounds with potential glycemic, anti-inflammatory, gut, and other health benefits. It also stressed that raw, unpasteurized camel milk poses microbial and zoonotic risks, underscoring that safety remains a key part of the story.

25 Mar 2026

New insights into acupoint sensitization in disease diagnosis and therapy

In both traditional acupuncture theory and modern medical experience, acupoints are central to therapeutic outcomes, yet their biological nature has remained controversial.

24 Mar 2026

Scientists turn red blood cells into long-lasting drug and imaging carriers in mice

A new preclinical study shows that red blood cells can be tagged in vivo and used as long-lasting carriers for imaging agents and therapies, opening a new route for safer drug delivery and vascular imaging.

23 Mar 2026

New dual blood test reduces false positives in Alzheimer's screening

Alzheimer's disease is characterised by the accumulation of two proteins in the brain: amyloid-beta and tau.

23 Mar 2026

AI-driven OCT imaging system enables precise wound healing assessment

No matter the size or severity, wounds on human skin are difficult to monitor while they heal. Biopsies disrupt the wound site and are too invasive for routine, repeated monitoring, and most medical imaging devices that could do the job are large, expensive and booked up with more pressing diagnostics.

23 Mar 2026

Study finds GLP-1 medicines cut fat while preserving muscle function

Researchers found that GLP-1 medicines caused weight loss mainly through fat reduction, with only modest decreases in absolute muscle mass and no disproportionate loss of muscle function. In mice, physical performance improved, while in a small 12-week human pilot trial, strength was preserved despite reduced thigh muscle size.

18 Mar 2026

Aptamer Group launches targeted radiopharmaceutical program

Aptamer Group plc, the developer of next‑generation synthetic binders for the life sciences industry, today announced the launch of a new targeted radiopharmaceutical program in collaboration with Radiopharmium Ltd, a UK-based specialist consultancy in radiopharmaceutical development.

From Aptamer Group 18 Mar 2026